ClinicalTrials.gg
CompletedNCT03856957Updated Feb 16, 2021

Serrated Lesions Detection With Endocuff-assisted Colonoscopy

An interventional study of Endocuff colonoscopy and control in Serrated Lesion, Adenoma and Colorectal Cancer, sponsored by Hospital Beatriz Ângelo. Completed at 1 site in Portugal. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-16.

Sponsored by Hospital Beatriz Ângelo · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jun 2018, registered Feb 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
257
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

Colorectal cancer (CRC) is a leading cause of morbidity and mortality worldwide, especially in Western countries. CRC is currently considered a preventable disease and screening has been endorsed by several societies, since it has been shown that screening and surveillance are effective in reducing both CRC incidence and mortality. However, recently, concern has risen regarding colonoscopy effectiveness, especially in the right colon. The most accepted explanation for this effectiveness variability is attributed to sessile serrated lesions (SSL), which are more frequent in the proximal colon, more difficult to detect because of their flat morphology and associated with interval CRC, which is the occurrence of CRC after screening colonoscopy and before the next scheduled procedure. Several techniques are emerging to increase the sensitivity of colonoscopy for pre-cancerous lesions, especially adenomas. Recently an endoscopic cap, the Endocuff, was developed to improve adenoma detection. Several studies demonstrated improved adenoma detection with Endocuff-assisted colonoscopy when compared with conventional colonoscopy. Still, the available data for its' role in detecting SSL is very limited. The aim of this randomized controlled trial is to evaluate the effectiveness of Endocuff-assisted colonoscopy in detection of colorectal SSL.

02

Conditions studied

  • Serrated Lesion
  • Adenoma
  • Colorectal Cancer

Keywords

  • Serrated Lesion
  • Endocuff
  • Detection
03

In context

Adenoma

183 studies on the registry are indexed under Adenoma; 28 are open to participants now.

This study's enrollment of 257 is below the median of 372 across 128 interventional studies indexed under Adenoma.

Browse Adenoma studies →

Lead sponsor

Hospital Beatriz Ângelo is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients undergoing elective colonoscopies

Exclusion criteria

Exclusion Criteria:

  • Known polyposis syndromes
  • Personal colorectal cancer history
  • Previous colorectal surgery
  • Severe diverticulosis
  • Colonic stricture
  • Inflammatory bowel disease
  • Primary sclerosing cholangitis
  • Pregnancy and breastfeeding
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
257 participants (actual)

Study arms

  • Experimental
    Endocuff colonoscopy

    Colonoscopy performed with Endocuff

    Device: Endocuff colonoscopy

  • Placebo comparator
    Conventional colonoscopy

    Colonoscopy performed without any device

    Device: control

Interventions

  • DeviceEndocuff colonoscopy

    Colonoscopy performed with Endocuff for mucosal inspection and interventions (eg. polypectomy).

  • Devicecontrol

    colonoscopy without endocuff

06

What researchers measure

Primary outcomes

  1. Average number of serrated lesions ≥ 10 mm detected per colonoscopy

    Average number of serrated lesions ≥ 10 mm detected per colonoscopy

    Time frame: immediate

Secondary outcomes

  1. Serrated lesions detection rate

    Number of patients with at least one serrated lesion/total number of participants

    Time frame: immediate

  2. Average number of serrated lesions < 10 mm detected per colonoscopy

    Average number of serrated lesions \< 10 mm detected per colonoscopy

    Time frame: immediate

  3. Average number of adenomas detected per colonoscopy

    Average number of adenomas detected per colonoscopy

    Time frame: immediate

  4. Adenoma detection rate

    Number of patients with at least one adenoma/total number of participants

    Time frame: immediate

  5. Adenocarcinoma detection rate

    Number of patients with at least one adenocarcinoma/total number of participants

    Time frame: immediate

  6. Cecal intubation rate

    Proportion of colonoscopies with cecal intubation x100

    Time frame: immediate

  7. Cecal incubation time

    time from the rectum to cecum in minutes

    Time frame: immediate

  8. Withdrawal time

    time from the cecum to the rectum in minutes

    Time frame: immediate

  9. Incidence of procedure related adverse events

    Number of adverse events

    Time frame: immediate

07

Study locations

1 site
  • Hospital Beatriz Ângelo
    Lisbon, Loures 2674-514, Portugal
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Mar 2019, 9 months.

Of 44 non-industry interventional studies with no phase under Adenoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 9 months is below that.

Counting every sponsor, half of 50 studies reached it within 28 months; a quarter within 17 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2019
First posted
Feb 27, 2019
StartActual
Jun 11, 2018
Primary completionActual
Mar 30, 2019
CompletionActual
Jul 1, 2019
Last update
Feb 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03856957
Lead sponsor
Hospital Beatriz Ângelo
Responsible party
Alexandre Ferreira (Dr, Hospital Beatriz Ângelo) — Principal investigator
First posted
Feb 27, 2019
Start date
Jun 11, 2018
Primary completion
Mar 30, 2019
Completion
Jul 1, 2019
Last update
Feb 16, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion